Critical Survey: Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation.

Insider and Institutional Ownership

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Coya Therapeutics and Madrigal Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95 million	14.19	-$21.23 million	($1.07)	-4.50
Madrigal Pharmaceuticals	$958.40 million	12.04	-$288.28 million	($12.89)	-38.74

Coya Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Coya Therapeutics and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Analyst Recommendations

This is a breakdown of recent recommendations for Coya Therapeutics and Madrigal Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1	0	6	0	2.71
Madrigal Pharmaceuticals	1	2	15	0	2.78

Coya Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 218.78%. Madrigal Pharmaceuticals has a consensus price target of $710.20, indicating a potential upside of 42.21%. Given Coya Therapeutics’ higher probable upside, research analysts clearly believe Coya Therapeutics is more favorable than Madrigal Pharmaceuticals.

Risk and Volatility

Coya Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, indicating that its share price is 204% less volatile than the S&P 500.

About Coya Therapeutics

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.